{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:22:41Z","timestamp":1788992561973,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s40744-024-00726-6","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T05:50:09Z","timestamp":1733377809000},"page":"67-84","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Tofacitinib Efficacy\/Safety in Patients with Ankylosing Spondylitis by Baseline Body Mass Index: A Post Hoc Analysis of Phase 2\/3 Trials"],"prefix":"10.1007","volume":"12","author":[{"given":"Hillary","family":"Norton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Sliwinska-Stanczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Hala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassel","family":"El-Zorkany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Stockert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajiv","family":"Mundayat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"726_CR1","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA. Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med. 2016;374:2563\u201374.","journal-title":"N Engl J Med"},{"key":"726_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","volume":"7","author":"W Zhu","year":"2019","unstructured":"Zhu W, He X, Cheng K, et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7:22.","journal-title":"Bone Res"},{"key":"726_CR3","doi-asserted-by":"publisher","first-page":"R108","DOI":"10.1186\/ar3833","volume":"14","author":"E Klingberg","year":"2012","unstructured":"Klingberg E, Lorentzon M, Mellstrom D, et al. Osteoporosis in ankylosing spondylitis\u2014prevalence, risk factors and methods of assessment. Arthritis Res Ther. 2012;14:R108.","journal-title":"Arthritis Res Ther"},{"key":"726_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/1759720X18783894","volume":"10","author":"E Nikiphorou","year":"2018","unstructured":"Nikiphorou E, Fragoulis GE. Inflammation, obesity and rheumatic disease: common mechanistic links. A narrative review. Ther Adv Musculoskelet Dis. 2018;10:157\u201367.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"726_CR5","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.3899\/jrheum.120595","volume":"39","author":"L Durcan","year":"2012","unstructured":"Durcan L, Wilson F, Conway R, Cunnane G, O\u2019Shea FD. Increased body mass index in ankylosing spondylitis is associated with greater burden of symptoms and poor perceptions of the benefits of exercise. J Rheumatol. 2012;39:2310\u20134.","journal-title":"J Rheumatol"},{"key":"726_CR6","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/ar3841","volume":"14","author":"S Ottaviani","year":"2012","unstructured":"Ottaviani S, Allanore Y, Tubach F, et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther. 2012;14:R115.","journal-title":"Arthritis Res Ther"},{"key":"726_CR7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.2312","volume":"5","author":"R Wang","year":"2022","unstructured":"Wang R, Dasgupta A, Ward MM. Predicting probability of response to tumor necrosis factor inhibitors for individual patients with ankylosing spondylitis. JAMA Netw Open. 2022;5: e222312.","journal-title":"JAMA Netw Open"},{"key":"726_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.3899\/jrheum.170094","volume":"44","author":"SE Ib\u00e1\u00f1ez Vodnizza","year":"2017","unstructured":"Ib\u00e1\u00f1ez Vodnizza SE, Nurmohamed MT, Visman IM, et al. Fat mass lowers the response to tumor necrosis factor-alpha blockers in patients with ankylosing spondylitis. J Rheumatol. 2017;44:1355\u201361.","journal-title":"J Rheumatol"},{"key":"726_CR9","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76:1340\u20137.","journal-title":"Ann Rheum Dis"},{"key":"726_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","volume":"80","author":"A Deodhar","year":"2021","unstructured":"Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021;80:1004\u201313.","journal-title":"Ann Rheum Dis"},{"key":"726_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002103","volume":"8","author":"AH Dikranian","year":"2022","unstructured":"Dikranian AH, Gonzalez-Gay MA, Wellborne F, et al. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies. RMD Open. 2022;8: e002103.","journal-title":"RMD Open"},{"key":"726_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/apt.16439","volume":"54","author":"FA Farraye","year":"2021","unstructured":"Farraye FA, Qazi T, Kotze PG, et al. The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme. Aliment Pharmacol Ther. 2021;54:429\u201340.","journal-title":"Aliment Pharmacol Ther"},{"key":"726_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001486","volume":"7","author":"JT Giles","year":"2021","unstructured":"Giles JT, Ogdie A, Gomez Reino JJ, et al. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. RMD Open. 2021;7: e001486.","journal-title":"RMD Open"},{"key":"726_CR14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/sj.ijo.0802609","volume":"28","author":"D Aronson","year":"2004","unstructured":"Aronson D, Bartha P, Zinder O, et al. Obesity is the major determinant of elevated C-reactive protein in subjects with the metabolic syndrome. Int J Obes Relat Metab Disord. 2004;28:674\u20139.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"726_CR15","doi-asserted-by":"crossref","unstructured":"McGonagle D, Ramonda R, Scagnellato L, Scriffignano S, Weddell J, Lubrano E. A strategy towards disentangling treatment refractory from misdiagnosed axial spondyloarthritis. Autoimmun Rev. 2024;23: 103405.","DOI":"10.1016\/j.autrev.2023.103405"},{"key":"726_CR16","doi-asserted-by":"crossref","unstructured":"Mease PJ, Liu M, Rebello S, et al. Characterization of patients with axial spondyloarthritis by enthesitis presence: data from the Corrona Psoriatic Arthritis\/Spondyloarthritis Registry. ACR Open Rheumatol. 2020;2:449\u201356.","DOI":"10.1002\/acr2.11154"},{"key":"726_CR17","first-page":"S133","volume":"23","author":"J Zochling","year":"2005","unstructured":"Zochling J, Braun J. Assessment of ankylosing spondylitis. Clin Exp Rheumatol. 2005;23:S133\u201341.","journal-title":"Clin Exp Rheumatol"},{"key":"726_CR18","unstructured":"Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286\u201391."},{"key":"726_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/ard.2008.094870","volume":"68","author":"C Lukas","year":"2009","unstructured":"Lukas C, Landew\u00e9 R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:18\u201324.","journal-title":"Ann Rheum Dis"},{"key":"726_CR20","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/archgenpsychiatry.2010.2","volume":"67","author":"FS Luppino","year":"2010","unstructured":"Luppino FS, de Wit LM, Bouvy PF, et al. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Arch Gen Psychiatry. 2010;67:220\u20139.","journal-title":"Arch Gen Psychiatry"},{"key":"726_CR21","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/BOR.0000000000000388","volume":"29","author":"PJ Mease","year":"2017","unstructured":"Mease PJ. Fibromyalgia, a missed comorbidity in spondyloarthritis: prevalence and impact on assessment and treatment. Curr Opin Rheumatol. 2017;29:304\u201310.","journal-title":"Curr Opin Rheumatol"},{"key":"726_CR22","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.jpain.2010.03.006","volume":"11","author":"A Okifuji","year":"2010","unstructured":"Okifuji A, Donaldson GW, Barck L, Fine PG. Relationship between fibromyalgia and obesity in pain, function, mood, and sleep. J Pain. 2010;11:1329\u201337.","journal-title":"J Pain"},{"key":"726_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13075-018-1644-6","volume":"20","author":"S Zhao","year":"2018","unstructured":"Zhao S, Thong D, Miller N, et al. The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis. Arthritis Res Ther. 2018;20:140.","journal-title":"Arthritis Res Ther"},{"key":"726_CR24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1093\/rheumatology\/key075.533","volume":"57","author":"SJ Duffield","year":"2018","unstructured":"Duffield SJ, Miller N, Zhao S, Goodson NJ. Concomitant fibromyalgia complicating chronic inflammatory arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2018;57:1453\u201360.","journal-title":"Rheumatology (Oxford)"},{"key":"726_CR25","first-page":"145","volume":"35","author":"J Rosas","year":"2017","unstructured":"Rosas J, Llinares-Tello F, Senabre-Gallego JM, et al. Obesity decreases clinical efficacy and levels of adalimumab in patients with ankylosing spondylitis. Clin Exp Rheumatol. 2017;35:145\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"726_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/annrheumdis-2011-200180","volume":"71","author":"HY Chung","year":"2012","unstructured":"Chung HY, Machado P, van der Heijde D, D\u2019Agostino MA, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis. 2012;71:809\u201316.","journal-title":"Ann Rheum Dis"},{"key":"726_CR27","first-page":"422","volume":"37","author":"CB McCulley","year":"2019","unstructured":"McCulley CB, Barton JL, Cannon GW, et al. Body mass index and persistence of conventional DMARDs and TNF inhibitors in rheumatoid arthritis. Clin Exp Rheumatol. 2019;37:422\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"726_CR28","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3390\/ijerph21060757","volume":"21","author":"Y Wu","year":"2024","unstructured":"Wu Y, Li D, Vermund SH. Advantages and limitations of the body mass index (BMI) to assess adult obesity. Int J Environ Res Public Health. 2024;21:757.","journal-title":"Int J Environ Res Public Health"},{"issue":"suppl 9","key":"726_CR29","first-page":"0405","volume":"74","author":"H Norton","year":"2022","unstructured":"Norton H, Sliwinska-Stanczyk P, Hala T, et al. Efficacy and safety of tofacitinib in patients with ankylosing spondylitis by baseline BMI: a post hoc analysis of Phase 2 and Phase 3 trials [abstract]. Arthritis Rheumatol. 2022;74(suppl 9):0405.","journal-title":"Arthritis Rheumatol"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00726-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00726-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00726-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:43:33Z","timestamp":1737477813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00726-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["726"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00726-6","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hillary Norton has received grants and\/or research support from AbbVie, Eli Lilly, Horizon, Novartis, and Scipher; has been an advisor for AbbVie, Amgen, AstraZeneca, Eli Lilly, Horizon, Janssen, Novartis, Pfizer Inc., Scipher, and UCB; and has been a member of the speakers\u2019 bureau for AbbVie, Amgen, Eli Lilly, Janssen, Horizon, Novartis, Sanofi-Aventis, and UCB. Paula Sliwinska-Stanczyk and Tomas Hala have no disclosures. Bassel El-Zorkany has received grants and\/or research support from Pfizer Inc. and Roche and has acted as a consultant for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly, Eva, Hekma, Inspire, Janssen, MSD, New Bridge, Novartis, Pfizer Inc., Roche, Sanofi-Aventis, and Servier. Lori\u00a0Stockert, Rajiv Mundayat, and Lisy Wang are employees and stockholders of Pfizer Inc. Christopher T. Ritchlin has acted as a consultant for AbbVie, Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc., and UCB and has received grants and\/or research support from AbbVie, Janssen, Pfizer Inc., and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Both trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Council for Harmonisation and were approved by the relevant Institutional Review Board and\/or Independent Ethics Committee of the investigational centers. All patients provided written, informed consent, which is applicable to all medical research conducted using data from these studies, including this post hoc analysis. As all patients provided informed consent, all of the data included in this analysis were covered by the original ethical review\/approval process. Consequently, no additional ethical review\/approval was required for this post hoc analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}